89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
27. November 2023 08:00 ET
|
89bio, Inc.
—Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests (NITs) of liver injury/inflammation and...
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
21. November 2023 16:01 ET
|
89bio, Inc.
SAN FRANCISCO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
12. November 2023 12:15 ET
|
89bio, Inc.
—Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic (F4) patients at week 24— —A...
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
08. November 2023 16:01 ET
|
89bio, Inc.
–Pegozafermin granted Breakthrough Therapy Designation (BTD) for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis– –Feedback from regulatory agencies on pegozafermin Phase 3...
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
17. Oktober 2023 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03. Oktober 2023 16:05 ET
|
89bio, Inc.
SAN FRANCISCO, Oct. 03, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
21. September 2023 08:00 ET
|
89bio, Inc.
–Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin– –Discussions with regulatory agencies regarding the NASH Phase 3 program planned for the...
89bio to Participate in the 2023 Cantor Global Healthcare Conference
20. September 2023 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
05. September 2023 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
09. August 2023 16:01 ET
|
89bio, Inc.
– Published data from ENLIVEN Phase 2b trial of pegozafermin in NASH in The New England Journal of Medicine; presented the data in a late-breaker session at the EASL International Liver Congress – –...